

**ATRIAL NATRIURETIC PEPTIDE
CONCENTRATIONS IN PREGNANCY
INDUCED HYPERTENTION (P. I. H.)**

THESIS

**SUBMITTED FOR THE PARTIAL FULFILLMENT
OF THE MASTER DEGREE IN OBSTETRICS AND GYNAECOLOGY**

BY

RANDA MAHMOUD AHMED

M. B. , B. Ch. (AIN SHAMS)

SUPERVISED BY

DR. AHMED RASHED M. RASHED

PROF. DR. HOSNA M. ABDEL RAHMAN

ASSIST. PROF. OF OBST.

PROF. OF CLINICAL CHEMISTRY TUDOR

AND GYNAECOL

BILHARZ RESEARCH INSTITUTE

AIN SHAMS UNIVERSITY


DR. ESSAM M. KHATER

LECTURER OF OBSTETRICS AND GYNAECOL

AIN SHAMS UNIVERSITY

**FACULTY OF MEDICINE
AIN SHAMS UNIVERSITY**

1991



سورة البقرة ٠٠ آية ٣٢



ACKNOWLEDGEMENT

Frist and Foremost I thank God the Benificent and Merciful.

I would like to express my cordial appreciation and sincere gratitude to **DR. AHMED RASHED M. RASHED**, Assist. Professor of Obstetrics and Gynaecology, Faculty of Medicine Ain Shams University, for giving me the utmost honour to work under his supervision and for his unfailing moral support, constructive criticism and continuous encouragement throughout the conduct of this work.

I would like to express my deep gratitude to **DR. ESSAM M. KHATER**, Lecturer of Obstetrics and Gynaecology, Faculty of Medicine, Ain Shams University for his great help, fruitful ideas and valuable advice.

I am particularly indepted to **PROFESSOR D. HUSNA M. ABDEL RAHMAN**, Professor of Clinical chemistry, Tudor Bilharz Research Institute for her valuable honest assistance, kind advice and unlimited generosity in time and effort.

My thanks also to my parents and my husband as
without their unfailing moral support, I wouldn't have
accomplished this work.

ABBREVIATION

ANP	:	Atrial Natriuretic peptide
cAMP	:	Cyclic adenosine monophosphate
cGMP	:	Cyclic guanosine 3'5' monophosphate
DOC	:	Deoxycorticosterone
HLA	:	Human leucocyte antigen
PIH	:	Pregnancy induced hypertension

CONTENTS

	Page
* INTRODUCTION AND AIM OF THE WORK.....	1
* REVIEW OF LITERATURE.....	5
- ATRIAL NATRIURETIC PEPTIDE (ANP).....	5
- Nomenclature.....	5
- Origin.....	6
- Chemical properties.....	7
- Biosynthesis.....	10
- Intracellular storage.....	13
- Metabolism and clearance.....	15
- Effects on cyclic nucleotides.....	17
- Control of ANP release.....	18
- Circadian variations of ANP.....	19
- ANP in normotensive pregnancy and in PIH.....	19
- Post partum ANP level.....	22
- ANP and the foetus.....	23
- Physiological effects of ANP.....	26
- PIH.....	37
* MATERIAL AND METHOD.....	53
* RESULTS.....	65
* DISCUSSION.....	76
* CONCLUSION.....	83
* SUMMARY.....	84
* REFERENCES.....	86
* ARABIC SUMMARY	

INTRODUCTION
&
AIM OF WORK

INTRODUCTION AND AIM OF THE WORK

Hypertensive disorders complicating pregnancy are common and form one of the great triade along with haemorrhage, infection and continues to be responsible for a large number of maternal deaths. [Cunningham *et al.*, 1989].

Pregnancy induced hypertension is a syndrome of unknown aetiology; different theories were postulated but none of them could stand the test of time [Pauerstein, 1987].

Cardiac atria have long been suspected of participating in the regulation of blood volume [Thomsen *et al.*, 1987], this has usually been ascribed to reflex stimulation of neural stretch receptors located in the subendocardium which results in enhanced urine flow and salt excretion [Ballermann and Brenner, 1985].

In 1981, De Bold *et al.* provided direct evidence for humoral mediator "atrial natriuretic peptide", by showing that saline extracts of cardiac atria, but not the ventricles, elicit a marked increase in urinary salt and water excretion when injected into normal rats.

Atrial natriuretic peptides are a group of biologically active peptides synthesized and secreted by the atrial myocytes. Three separate forms (α , β , τ) of the peptide have been isolated from human atrial cells [Kangawa et al., 1985]. The biologically active circulating form of the atrial natriuretic peptide (ANP) is a 28 amino acid structure derived from a large molecular weight prohormone [Gutkowska et al., and Kangawa et al., 1985].

Besides the significant natriuretic and diuretic effects, atrial natriuretic peptide induces an increase in renal blood flow and glomerular filtration rate. However the actual mechanism (s) responsible for natriuresis remains unclear with evidence consistent for both haemodynamically induced natriuresis and inhibitory effect upon tubular sodium reabsorption [Borenstein et al., 1983]. ANP has also been shown to inhibit vascular smooth muscle contraction induced by angiotensin II and noradrenaline and it reduces the secretion of both renin and aldosterone. [Thomsen, et al., 1987]. Thus it complements the activity of other known regulators of blood pressure and blood volume [Bond et al., 1989].

In fact plasma levels of ANP change in various pathologic states associated with generalized oedema or volume expansion such as congestive heart failure, renal failure and some hypertensive disorders [Sato et al., 1986].

Atrial stretch consequent to haemodynamic changes or volume expansion appears to be one of the most important stimuli for atrial natriuretic peptide release [Burnett *et al.*, 1986 and Sato *et al.*, 1986]. ANP secretion is also increased in response to high sodium diet and conversely, a low sodium diet decreases its plasma concentrations [Sagnella *et al.*, 1985].

A striking change in haemodynamics occurs in women during pregnancy that may alter plasma ANP levels [Hirai *et al.*, 1988]. Normal pregnancy is characterized by expanded plasma volume, [Gallery *et al.*, 1979 and Thomsen *et al.*, 1987] therefore elevated levels of plasma ANP in normal pregnancy might be expected. There is no consensus in the literature that atrial natriuretic peptide is increased in pregnancy.

A role for ANP in pregnancy induced hypertension has also been proposed. Since patients with pregnancy induced hypertension, typically have decreased plasma volume, normal or even low plasma ANP concentrations would have been expected. Conversely Thomsen *et al.* [1987] and Miyamoto *et al.* [1988] reported substantively increased ANP levels in those patients with PIH. However the role of endogenous atrial natriuretic peptide in hypertensive disorders is debatable.

The present study aims to assess the effect of pregnancy as well as pregnancy induced hypertension on plasma atrial natriuretic peptide concentrations in a trial to find its significant role in PIH state. Also to correlate the plasma ANP level with the clinical and other biochemical findings in this study.

**REVIEW
OF
LITERATURE**

ATRIAL NATRIURETIC PEPTIDE

Since its isolation, 1981, atrial natriuretic peptide has received attention as a potentially important mediator of volume homeostasis [Bond et al., 1989].

Atrial natriuretic peptide acts on the kidney to promote excretion of salt and water, thus decreasing the extracellular fluid volume and maintaining homeostasis [Ballerman and Brunner, 1986].

Beside the natriuretic and diuretic effects, atrial natriuretic peptide (ANP) inhibits vasoconstriction induced by angiotensin II and nor adrenaline and reduces secretion of both renin and aldosterone. [Atlas et al., 1986 and Thomsen et al., 1987].

Nomenclature

Atrial natriuretic peptide was described by different authors and gave it different names as: atrial natriuretic factor I, II, III [Atlas et al., 1984], α, β and human natriuretic polypeptides [Kangawa and Matsu, 1984].

Atrial [Ballermann and Brenner, 1985] cardionatriin [Mills, 1984], atriopeptin I, II, III [Geller et al., 1984] and auriculin [Maack et al., 1984].

Origin

Atrial natriuretic peptide is a hormone synthesized in atrial myocytes, stored there in granules and released as a result of increased intraatrial pressure or atrial stretching [Yamaji et al., 1985].

Also it has been shown that foetal umbilical arterial level of ANP is higher than the umbilical venous level or maternal plasma level. This implies that there may be a primary foetal synthesis of atrial natriuretic peptide and the localization of placental ANP receptors supports a functional role of circulating foetal ANP [Hatijis et al., 1988].

Robbillard et al. (1988) carried out an important work on human foetuses to determine whether an increase in intravascular volume load would stimulate ANP secretion in the foetuses as it does in the adult. He found that ANP is present as a circulating hormone, in the human foetus by mid gestation at which time foetal release of ANP is increased in response to intravascular volume expansion.